An FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS)...


An FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS) Signifor, a treatment for patients with Cushing's disease who require medical therapeutic intervention. The drug is the first of its kind for this potentially debilitating endocrine disorder caused by a pituitary tumor that triggers excess cortisol. Phase III clinical trials showed patients who used Signifor experienced a rapid and sustained decrease in mean cortisol levels.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs